West names Michel Lagarde CEO, succeeding Eric Green effective August 31, 2026
West Pharmaceutical Services said its Board appointed Michel Lagarde, formerly Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, as President and Chief Executive Officer effective August 31, 2026, replacing Eric M. Green, who is retiring. Lead Independent Director Robert F. Friel will become Board Chair on the same date, and Mr. Lagarde will join the Board as a director.
Key points
- Mr. Lagarde's annual base salary is $1,175,000, with a target annual incentive of 125% of salary, or $1,468,750.
- His 2026 long-term incentive award has a total grant value of $8,611,111, and a one-time sign-on grant has a total grant date value of $6,875,000.
- Matching inducement grants are based on his personal stock purchases between May 31, 2026 and the start date, capped at $2,500,000.
- Mr. Green's transition was first disclosed on March 9, 2026, when he told the Board on March 6, 2026 of his intent to retire.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.